What Happened

Helus Pharma announced its fiscal year 2026 financial results, including a $50 million underwritten offering to support its Phase 3 HLP003 trial. The Phase 3 APPROACH study for Major Depressive Disorder has surpassed 88% enrollment, with topline data expected in Q4 2026. The company also reported Phase 2 results for HLP004 in Generalized Anxiety Disorder, showing significant symptom improvement.

Who Is Affected

Patients with Major Depressive Disorder and Generalized Anxiety Disorder are directly impacted by Helus Pharma’s clinical trials. Healthcare providers, payers, and mental health organizations are also key stakeholders as the company moves closer to commercialization.

Market Impact

• Helus Pharma’s $50M funding strengthens its financial position for Phase 3 trials and potential FDA approval.
• The Phase 3 APPROACH study’s progress indicates a potential new treatment option for Major Depressive Disorder by 2028.
• Phase 2 results for HLP004 suggest a promising adjunctive therapy for Generalized Anxiety Disorder.

What to Watch

Monitor the topline data readout for the Phase 3 APPROACH study in Q4 2026 and the design completion of the next HLP004 study by Q3 2026. These milestones will be critical for Helus Pharma’s path to commercialization and regulatory approval.